Munkhzul et al. [72] reported that isorhamnetin reduces steatosis and fibrosis in non-alcoholic steatohepatitis (NASH) mouse models by downregulating inflammatory factors, such as TGF-β, in hepatic stellate cells (HSCs) and inhibiting macrophage infiltration, thereby preventing HSC activation. Here, TGFB1 is linked to metabolic dysfunction-associated steatohepatitis.